The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Open accessAbstract
Agonists of the nuclear receptor PPARγ are therapeutically used to combat hyperglycaemia associated with the metabolic syndrome and type 2 diabetes. In spite of being effective in normalization of blood glucose levels, the currently used PPARγ agonists from the thiazolidinedione type have serious side effects, making the discovery of novel ligands highly relevant. Natural products have proven historically to be a promising pool of structures for drug discovery, and a significant research effort has recently been undertaken to explore the PPARγ-activating potential of a wide range of natural products originating from traditionally used medicinal plants or dietary sources. The majority of identified compounds are selective PPARγ modulators (SPPARMs), transactivating the expression of PPARγ-dependent reporter genes as partial agonists. Those natural PPARγ ligands have different binding modes to the receptor in comparison to the full thiazolidinedione agonists, and on some occasions activate in addition PPARα (e.g. genistein, biochanin A, sargaquinoic acid, sargahydroquinoic acid, resveratrol, amorphastilbol) or the PPARγ-dimer partner retinoid X receptor (RXR; e.g. the neolignans magnolol and honokiol). A number of in vivo studies suggest that some of the natural product activators of PPARγ (e.g. honokiol, amorfrutin 1, amorfrutin B, amorphastilbol) improve metabolic parameters in diabetic animal models, partly with reduced side effects in comparison to full thiazolidinedione agonists. The bioactivity pattern as well as the dietary use of several of the identified active compounds and plant extracts warrants future research regarding their therapeutic potential and the possibility to modulate PPARγ activation by dietary interventions or food supplements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Indian Medicinal Plants: An Illustrated Dictionary
(2007) · Springer eBooks · doi:10.1007/978-0-387-70638-2 · Cited by 9,201
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · cited 1×
“Endogenous ligands for PPARg include fatty acids and prostanoids [19,35] that act as weak agonists compared to the strong synthetic thiazolidinedione agonists [36,37].”
BackgroundForman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,956
Wolber, G., & Langer, T. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049885e · Cited by 1,954
NF-κB, Inflammation, and Metabolic Disease
Baker, R. G., Hayden, M. S., & Ghosh, S. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.008 · Cited by 1,952
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
Furuhashi, M., & Hotamisligil, G. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2589 · Cited by 1,785
PPARs and the complex journey to obesity
Evans, R. M., Barish, G. D., & Wang, Y.-X. (2004) · Nature Medicine · doi:10.1038/nm1025 · Cited by 1,602
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Farnsworth, N., Akerele, O., & Bingel, A. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90016-x · Cited by 1,362
Peroxisome proliferator-activated receptor a target genes
Mandard, S., M�ller, M., & Kersten, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3216-3 · Cited by 1,218
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene
Fajas, L., Auboeuf, D., Raspé, E., Schoonjans, K., Lefebvre, A.-M., Saladin, R., Najib, J., Laville, M., Fruchart, J.-C., Deeb, S., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18779 · Cited by 1,188
Lessons from natural molecules
Clardy, J., & Walsh, C. (2004) · Nature · doi:10.1038/nature03194 · Cited by 1,171
Grygiel-Górniak, B. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-17 · Cited by 1,079
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5
Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Boström, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Blüher, M., et al. (2010) · Nature · doi:10.1038/nature09291 · Cited by 875
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Bensinger, S. J., & Tontonoz, P. (2008) · Nature · doi:10.1038/nature07202 · Cited by 810
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Vidal-Puig, A. J., Considine, R. V., Jimenez-Liñan, M., Werman, A., Pories, W. J., Caro, J. F., & Flier, J. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119424 · Cited by 786
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Fatty acid metabolism: Target for metabolic syndrome
Wakil, S. J., & Abu-Elheiga, L. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800079-jlr200 · Cited by 731
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Lemberger, T., Desvergne, B., & Wahli, W. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.335 · Cited by 712
Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 697
Brasnyó, P., Molnár, G. A., Mohás, M., Markó, L., Laczy, B., Cseh, J., Mikolás, E., Szijártó, I. A., Mérei, Á., Halmai, R., et al. (2011) · British Journal of Nutrition · doi:10.1017/s0007114511000316 · Cited by 678
Evolution of the nuclear receptor gene superfamily.
Laudet, V., Hänni, C., Coll, J., Catzeflis, F., & Stéhelin, D. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05139.x · Cited by 666
An overview on biological mechanisms of PPARs
KOTA, B., HUANG, T., & ROUFOGALIS, B. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 666
Zhu, Y., Qi, C., Korenberg, J. R., Chen, X. N., Noya, D., Rao, M. S., & Reddy, J. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7921 · Cited by 653
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
PPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641
Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 629
Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells
Glass, C. K., & Saijo, K. (2010) · Nature Reviews Immunology · doi:10.1038/nri2748 · Cited by 619
PPARγ, the ultimate thrifty gene
Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., Ali, F., Sholley, C., Worrall, C., & Kelman, J. A. (2010) · JAMA · doi:10.1001/jama.2010.920 · Cited by 512
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
FORD, E. S., LI, C., & ZHAO, G. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00078.x · Cited by 471
Potent Inhibitory Effect of Troglitazone on Carotid Arterial Wall Thickness in Type 2 Diabetes
Minamikawa, J. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.5.1818 · Cited by 461
Structural basis for the activation of PPARγ by oxidized fatty acids
Itoh, T., Fairall, L., Amin, K., Inaba, Y., Szanto, A., Balint, B. L., Nagy, L., Yamamoto, K., & Schwabe, J. W. R. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1474 · Cited by 457
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Cao, Y. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3055 · Cited by 442
Medina-Gomez, G., Gray, S. L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., Curtis, R. K., Jimenez-Linan, M., Blount, M., Yeo, G. S. H., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030064 · Cited by 430
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Liberato, M. V., Nascimento, A. S., Ayers, S. D., Lin, J. Z., Cvoro, A., Silveira, R. L., Martínez, L., Souza, P. C. T., Saidemberg, D., Deng, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036297 · Cited by 411
Mezei, O., Shay, N., Banz, W. J., Steger, R. W., Peluso, M. R., & Winters, T. A. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.5.1238 · Cited by 401
Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor.
Gearing, K. L., Göttlicher, M., Teboul, M., Widmark, E., & Gustafsson, J. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.4.1440 · Cited by 395
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
Natural Product-likeness Score and Its Application for Prioritization of Compound Libraries
Ertl, P., Roggo, S., & Schuffenhauer, A. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700286x · Cited by 387
Wong, K. H., Li, G. Q., Li, K. M., Razmovski-Naumovski, V., & Chan, K. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.02.001 · Cited by 373
Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM
Ghazzi, M. N., Perez, J. E., Antonucci, T. K., Driscoll, J. H., Huang, S. M., Faja, B. W., The Troglitazone Study Group, & Whitcomb, R. W. (1997) · Diabetes · doi:10.2337/diab.46.3.433 · Cited by 366
ZOETE, V, GROSDIDIER, A., & MICHIELIN, O. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.01.007 · Cited by 358
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado-Lopez, F., & Moore-Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 354
The Prevalence of Metabolic Syndrome in Children: A Systematic Review of the Literature
Friend, A., Craig, L., & Turner, S. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0122 · Cited by 354
Fang, X.-K., Gao, J., & Zhu, D.-N. (2008) · Life Sciences · doi:10.1016/j.lfs.2007.12.021 · Cited by 350
Raskin, P., Rendell, M., Riddle, M. C., Dole, J. F., Freed, M. I., Rosenstock, J., & For the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1226 · Cited by 345
Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus
Schwartz, S., Raskin, P., Fonseca, V., & Graveline, J. F. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381302 · Cited by 331
Transcriptional coregulators in the control of energy homeostasis
Feige, J. N., & Auwerx, J. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.04.001 · Cited by 325
Dang, Z.-C., Audinot, V., Papapoulos, S. E., Boutin, J. A., & Löwik, C. W. G. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209483200 · Cited by 323
Phillips, L. S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E. B., Salzman, A., & the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.2.308 · Cited by 302
Vogl, S., Picker, P., Mihaly-Bison, J., Fakhrudin, N., Atanasov, A. G., Heiss, E. H., Wawrosch, C., Reznicek, G., Dirsch, V. M., Saukel, J., et al. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.06.007 · Cited by 299
Self-citationNatural Products as a Foundation for Drug Discovery
Beutler, J. A. (2009) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0911s46 · Cited by 296
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
Maggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286
Werman, A., Hollenberg, A., Solanes, G., Bjørbæk, C., Vidal-Puig, A. J., & Flier, J. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.20230 · Cited by 282
Schupp, M., Clemenz, M., Gineste, R., Witt, H., Janke, J., Helleboid, S., Hennuyer, N., Ruiz, P., Unger, T., Staels, B., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3442 · Cited by 274
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
OGIHARA, T., RAKUGI, H., IKEGAMI, H., MIKAMI, H., & MASUO, K. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)96214-5 · Cited by 274
HUANG, T., PENG, G., KOTA, B., LI, G., YAMAHARA, J., ROUFOGALIS, B., & LI, Y. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.009 · Cited by 272
Sears, I. B., MacGinnitie, M. A., Kovacs, L. G., & Graves, R. A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3410 · Cited by 270
Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression
Hotta, M., Nakata, R., Katsukawa, M., Hori, K., Takahashi, S., & Inoue, H. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m900255-jlr200 · Cited by 260
Knouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-14 · Cited by 246
Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
The Troglitazone study group, Kumar, S., Boulton, A. J. M., Beck-Nielsen, H., Berthezene, F., Muggeo, M., Persson, B., Spinas, G. A., Donoghue, S., Lettis, S., et al. (1996) · Diabetologia · doi:10.1007/bf00418542 · Cited by 236
Hirose, H., Kawai, T., Yamamoto, Y., Taniyama, M., Tomita, M., Matsubara, K., Okazaki, Y., Ishii, T., Oguma, Y., Takei, I., et al. (2002) · Metabolism · doi:10.1053/meta.2002.30506 · Cited by 235
Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230
Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-γActivation
Jacob, A., Wu, R., Zhou, M., & Wang, P. (2007) · PPAR Research · doi:10.1155/2007/89369 · Cited by 228
hPPARgamma Ligand binding domain in complex with 4-HDHA: 2vv1
Itoh, T., Fairall, L., & Schwabe, J. W. R. (2008) · Worldwide Protein Data Bank · doi:10.2210/pdb2vv1/pdb · Cited by 223
Transcription coactivators for peroxisome proliferator-activated receptors
YU, S., & REDDY, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.01.008 · Cited by 222
Takahashi, N., Kawada, T., Goto, T., Yamamoto, T., Taimatsu, A., Matsui, N., Kimura, K., Saito, M., Hosokawa, M., Miyashita, K., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02390-6 · Cited by 221
PPARγ in human and mouse physiology
HEIKKINEN, S., AUWERX, J., & ARGMANN, C. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.03.006 · Cited by 221
Rau, O., Wurglics, M., Paulke, A., Zitzkowski, J., Meindl, N., Bock, A., Dingermann, T., Abdel-Tawab, M., & Schubert-Zsilavecz, M. (2006) · Planta Medica · doi:10.1055/s-2006-946680 · Cited by 219
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors
Lalloyer, F., & Staels, B. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179689 · Cited by 216
Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive Patients
Raji, A., Seely, E. W., Bekins, S. A., Williams, G. H., & Simonson, D. C. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.172 · Cited by 215
Hepatic Failure in a Patient Taking Rosiglitazone
Forman, L. M., Simmons, D. A., & Diamond, R. H. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00005 · Cited by 212
Amorfrutins are potent antidiabetic dietary natural products
Weidner, C., de Groot, J. C., Prasad, A., Freiwald, A., Quedenau, C., Kliem, M., Witzke, A., Kodelja, V., Han, C.-T., Giegold, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116971109 · Cited by 211
Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01707.x · Cited by 209 · cited 1×
“In spite of its benefits in cardiovascular disease, troglitazone was removed from the market because it induced severe to fatal hepatotoxicity that outweighed its benefits for patients with diabetes [79–85].”
BackgroundLee, Y. K., Lee, W. S., Hwang, J. T., Kwon, D. Y., Surh, Y. J., & Park, O. J. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf802737z · Cited by 204
Genetic Modulation of PPARγ Phosphorylation Regulates Insulin Sensitivity
Rangwala, S. M., Rhoades, B., Shapiro, J. S., Rich, A. S., Kim, J. K., Shulman, G. I., Kaestner, K. H., & Lazar, M. A. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00274-0 · Cited by 204
Chuang, C.-C., Martinez, K., Xie, G., Kennedy, A., Bumrungpert, A., Overman, A., Jia, W., & McIntosh, M. K. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29807 · Cited by 204
The Small Molecule Harmine Is an Antidiabetic Cell-Type-Specific Regulator of PPARγ Expression
Waki, H., Park, K. W., Mitro, N., Pei, L., Damoiseaux, R., Wilpitz, D. C., Reue, K., Saez, E., & Tontonoz, P. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.03.010 · Cited by 202
Peroxisome proliferator-activated receptor agonists
Willson, T. M., & Wahli, W. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80015-4 · Cited by 198
Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report
Al-Salman, J., Arjomand, H., Kemp, D. G., & Mittal, M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00006 · Cited by 196
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Troglitazone-induced liver failure: a case study
Graham, D. J., Green, L., Senior, J. R., & Nourjah, P. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01529-2 · Cited by 186
Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR‐γ signal pathways
Hwang, J., Lee, M., Kim, H., Sung, M., Kim, H. Y., Kim, M. S., & Kwon, D. Y. (2009) · Phytotherapy Research · doi:10.1002/ptr.2606 · Cited by 185
O’Sullivan, S. E., Tarling, E. J., Bennett, A. J., Kendall, D. A., & Randall, M. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.121 · Cited by 183
Iwamoto, Y., Kosaka, K., Kuzuya, T., Akanuma, Y., Shigeta, Y., & Kaneko, T. (1996) · Diabetes Care · doi:10.2337/diacare.19.2.151 · Cited by 179
Tzameli, I., Fang, H., Ollero, M., Shi, H., Hamm, J. K., Kievit, P., Hollenberg, A. N., & Flier, J. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405346200 · Cited by 178
Structural Insight into PPARγ Activation Through Covalent Modification with Endogenous Fatty Acids
Waku, T., Shiraki, T., Oyama, T., Fujimoto, Y., Maebara, K., Kamiya, N., Jingami, H., & Morikawa, K. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.039 · Cited by 178
Tack, C. J. J., Ong, M. K. E., Lutterman, J. A., & Smits, P. (1998) · Diabetologia · doi:10.1007/s001250050948 · Cited by 177
Siddiqui, A. M., Cui, X., Wu, R., Dong, W., Zhou, M., Hu, M., Simms, H. H., & Wang, P. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000221921.71300.bf · Cited by 174
Covalent Peroxisome Proliferator-activated Receptor γ Adduction by Nitro-fatty Acids
Schopfer, F. J., Cole, M. P., Groeger, A. L., Chen, C.-S., Khoo, N. K. H., Woodcock, S. R., Golin-Bisello, F., Motanya, U. N., Li, Y., Zhang, J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091512 · Cited by 171
Shen, P., Liu, M., Ng, T., Chan, Y., & Yong, E. L. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.4.899 · Cited by 170
Isa, Y., Miyakawa, Y., Yanagisawa, M., Goto, T., Kang, M., Kawada, T., Morimitsu, Y., Kubota, K., & Tsuda, T. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.046 · Cited by 170
PPARγ in immunity and inflammation: cell types and diseases
Széles, L., Törőcsik, D., & Nagy, L. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.005 · Cited by 167
Touyz, R. M., & Schiffrin, E. L. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.014 · Cited by 166
Higgins, L. S., & DePaoli, A. M. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28449e · Cited by 166
Vareed, S. K., Reddy, M. K., Schutzki, R. E., & Nair, M. G. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.094 · Cited by 166
Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARα
Kim, S., Shin, H.-J., Kim, S. Y., Kim, J. H., Lee, Y. S., Kim, D.-H., & Lee, M.-O. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.03.011 · Cited by 160
Jungbauer, A., & Medjakovic, S. (2012) · Maturitas · doi:10.1016/j.maturitas.2011.12.009 · Cited by 159
Nuclear Receptors and Inflammation Control: Molecular Mechanisms and Pathophysiological Relevance
Huang, W. J. M., & Glass, C. K. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.191189 · Cited by 157
The Local Food-Nutraceuticals Consortium (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.06.005 · Cited by 155
Reka, A. K., Kurapati, H., Narala, V. R., Bommer, G. T., Chen, J., Standiford, T. J., & Keshamouni, V. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0570 · Cited by 154
Salam, N. K., Huang, T. H.-W., Kota, B. P., Kim, M. S., Li, Y., & Hibbs, D. E. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00606.x · Cited by 149
Christodoulides, C., & Vidal‐Puig, A. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.014 · Cited by 147
Matching the power of high throughput screening to the chemical diversity of natural products
Henrich, C. J., & Beutler, J. A. (2013) · Natural Product Reports · doi:10.1039/c3np70052f · Cited by 144
Honokiol: A non-adipogenic PPARγ agonist from nature
Atanasov, A. G., Wang, J. N., Gu, S. P., Bu, J., Kramer, M. P., Baumgartner, L., Fakhrudin, N., Ladurner, A., Malainer, C., Vuorinen, A., et al. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.06.021 · Cited by 137
Self-citationPeroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics?
Han, S., & Roman, J. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328011e67d · Cited by 135
Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPα gene expression
Shang, W., Yang, Y., Jiang, B., Jin, H., Zhou, L., Liu, S., & Chen, M. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.10.021 · Cited by 129
Ppars, metabolic disease and atherosclerosis
Fruchart, J., Staels, B., & Duriez, P. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0871 · Cited by 129
Fang, F., Kang, Z., & Wong, C. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900119 · Cited by 127
Isorhamnetin Represses Adipogenesis in 3T3‐L1 Cells
Lee, J., Jung, E., Lee, J., Kim, S., Huh, S., Kim, Y., Kim, Y., Byun, S. Y., Kim, Y., & Park, D. (2008) · Obesity · doi:10.1038/oby.2008.472 · Cited by 125
Wound Healing Potential of Elaeis guineensis Jacq Leaves in an Infected Albino Rat Model
Sasidharan, S., Nilawatyi, R., Xavier, R., Latha, L. Y., & Rajoo, A. (2010) · Molecules · doi:10.3390/molecules15053186 · Cited by 123
Füllert, S., Schneider, F., Haak, E., Rau, H., Badenhoop, K. W. J., Lübben, G., Usadel, K.-H., & Konrad, T. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020963 · Cited by 122
Changes in white adipose tissue metabolism induced by resveratrol in rats
Alberdi, G., Rodríguez, V. M., Miranda, J., Macarulla, M. T., Arias, N., Andrés‐Lacueva, C., & Portillo, M. P. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-29 · Cited by 121
Voloshyna, I., Hai, O. Y., Littlefield, M. J., Carsons, S. E., & Reiss, A. B. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.08.024 · Cited by 120
Citral, a component of lemongrass oil, activates PPARα and γ and suppresses COX-2 expression
Katsukawa, M., Nakata, R., Takizawa, Y., Hori, K., Takahashi, S., & Inoue, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.07.004 · Cited by 120
The next generation of PPAR drugs: Do we have the tools to find them?
SHEARER, B. G., & Billin, A. N. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.005 · Cited by 119
Na, H., & Surh, Y. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00488-x · Cited by 119
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 115
Mode of Peroxisome Proliferator-Activated Receptor γ Activation by Luteolin
Puhl, A. C., Bernardes, A., Silveira, R. L., Yuan, J., Campos, J. C. L. D. O., Saidemberg, D. M., Palma, M. S., Čvoro, A., Ayers, S. D., Webb, P., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076216 · Cited by 114
Benhaddou-Andaloussi, A., Martineau, L. C., Vallerand, D., Haddad, Y., Afshar, A., Settaf, A., & Haddad, P. S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01131.x · Cited by 112
Wong, V. K. W., Chiu, P., Chung, S. S. M., Chow, L. M. C., Zhao, Y., Yang, B. B., & Ko, B. C. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0209 · Cited by 112
CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure
Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., & Bass, N. M. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005405526283 · Cited by 111
Gong, Z., Huang, C., Sheng, X., Zhang, Y., Li, Q., Wang, M., Peng, L., & Zang, Y. Q. (2008) · Endocrinology · doi:10.1210/en.2008-0322 · Cited by 111
Han, K. L., Jung, M. H., Sohn, J. H., & Hwang, J. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.110 · Cited by 111
Sato, M., Tai, T., Nunoura, Y., Yajima, Y., Kawashima, S., & Tanaka, K. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.81 · Cited by 107
Treatment of active psoriatic arthritis with the PPAR ligand pioglitazone: an open-label pilot study
Bongartz, T., Coras, B., VOGT, T. M., Schölmerich, J., & Müller-Ladner, U. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh423 · Cited by 107
Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells
Choi, S., Cha, B., Lee, Y., Yonezawa, T., Teruya, T., Nagai, K., & Woo, J. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.04.001 · Cited by 106
An Autopsy Case of Troglitazone-Induced Fulminant Hepatitis
Shibuya, A., Watanabe, M., Fujita, Y., Saigenji, K., Kuwao, S., Takahashi, H., & Takeuchi, H. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2140 · Cited by 104
Shin, D. W., Kim, S. N., Lee, S. M., Lee, W., Song, M. J., Park, S. M., Lee, T. R., Baik, J.-H., Kim, H. K., Hong, J., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.09.033 · Cited by 103
Resveratrol and Its Metabolites Bind to PPARs
Calleri, E., Pochetti, G., Dossou, K. S. S., Laghezza, A., Montanari, R., Capelli, D., Prada, E., Loiodice, F., Massolini, G., Bernier, M., et al. (2014) · ChemBioChem · doi:10.1002/cbic.201300754 · Cited by 102
Kuroyanagi, K., Kang, M., Goto, T., Hirai, S., Ohyama, K., Kusudo, T., Yu, R., Yano, M., Sasaki, T., Takahashi, N., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.119 · Cited by 100
Oregano: A Source for Peroxisome Proliferator-Activated Receptor γ Antagonists
Mueller, M., Lukas, B., Novak, J., Simoncini, T., Genazzani, A. R., & Jungbauer, A. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf802298w · Cited by 99
Takahashi, N., Goto, T., Taimatsu, A., Egawa, K., Kato, S., Kusudo, T., Sakamoto, T., Ohyane, C., Lee, J., Kim, Y.-I., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.162 · Cited by 98
Floyd, Z. E., Wang, Z. Q., Kilroy, G. E., & Cefalu, W. T. (2008) · Metabolism · doi:10.1016/j.metabol.2008.04.006 · Cited by 98
Ulrich, S., Loitsch, S. M., Rau, O., von Knethen, A., Brüne, B., Schubert-Zsilavecz, M., & Stein, J. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2777 · Cited by 95
Park, J.-Y., Kawada, T., Han, I., Kim, B.-S., Goto, T., Takahashi, N., Fushiki, T., KURATA, T., & Yu, R. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.084 · Cited by 95
Kuroda, M., Mimaki, Y., Sashida, Y., Mae, T., Kishida, H., Nishiyama, T., Tsukagawa, M., Konishi, E., Takahashi, K., Kawada, T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.052 · Cited by 95
Sohn, E. J., Kim, C., Kim, Y. S., Jung, D. H., Jang, D. S., Lee, Y. M., & Kim, J. S. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.09.037 · Cited by 94
Analysis of traditional knowledge in medicinal plants used by Yuan in Thailand
Inta, A., Trisonthi, P., & Trisonthi, C. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.06.047 · Cited by 92
Kennedy, A. J., Overman, A., LaPoint, K., Hopkins, R. G., West, T., Chuang, C., Martinez, K., Bell, D., & McIntosh, M. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800258-jlr200 · Cited by 88
Activation of the nuclear receptor PPARγ by metabolites isolated from sage (Salvia officinalis L.)
Christensen, K. B., Jørgensen, M. E., Kotowska, D., Petersen, R. K., Kristiansen, K., & Christensen, L. P. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.07.054 · Cited by 85
Phenolics from Glycyrrhiza glabra roots and their PPAR-γ ligand-binding activity
Kuroda, M., Mimaki, Y., Honda, S., Tanaka, H., Yokota, S., & Mae, T. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.11.027 · Cited by 84
Fakhrudin, N., Ladurner, A., Atanasov, A. G., Heiß, E. H., Baumgartner, L., Markt, P., Schuster, D., Ellmerer, E. P., Wolber, G., Rollinger, J. M., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.062141 · Cited by 84
Self-citationCho, N., & Momose, Y. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786413474 · Cited by 81
Beaudoin, M., Snook, L. A., Arkell, A. M., Simpson, J. A., Holloway, G. P., & Wright, D. C. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00200.2013 · Cited by 81
Zhang, M., Deng, C., Zheng, J., Xia, J., & Sheng, D. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.02.013 · Cited by 80
Kim, S., Choi, H. Y., Lee, W., Park, G.-M., Shin, W. S., & Kim, Y. K. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.09.011 · Cited by 79
Balakumar, P., & Kathuria, S. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01938.x · Cited by 78
Structural Characterization of Amorfrutins Bound to the Peroxisome Proliferator-Activated Receptor γ
de Groot, J. C., Weidner, C., Krausze, J., Kawamoto, K., Schroeder, F. C., Sauer, S., & Büssow, K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3013272 · Cited by 78
Xie, L.-W., Atanasov, A. G., Guo, D.-A., Malainer, C., Zhang, J.-X., Zehl, M., Guan, S.-H., Heiss, E. H., Urban, E., Dirsch, V. M., et al. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.01.029 · Cited by 76
Self-citationChristensen, K. B., Minet, A. D., Svenstrup, H., Grevsen, K., Zhang, H., Schräder, E., Rimbach, G. H., Wein, S., Wolffram, S., Kristiansen, K., et al. (2009) · Phytotherapy Research · doi:10.1002/ptr.2782 · Cited by 75
Weidner, C., Wowro, S. J., Freiwald, A., Kawamoto, K., Witzke, A., Kliem, M., Siems, K., Müller‐Kuhrt, L., Schroeder, F. C., & Sauer, S. (2013) · Diabetologia · doi:10.1007/s00125-013-2920-2 · Cited by 74
Role of PPARγ in macrophage biology and atherosclerosis
Zhang, L., & Chawla, A. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.10.006 · Cited by 74
Treating diabetes today: a matter of selectivity of sulphonylureas
Seino, S., Takahashi, H., Takahashi, T., & Shibasaki, T. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2011.01507.x · Cited by 73
Atanasov, A. G., Blunder, M., Fakhrudin, N., Liu, X., Noha, S. M., Malainer, C., Kramer, M. P., Cocic, A., Kunert, O., Schinkovitz, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061755 · Cited by 72
Self-citationIdentification of a Naturally Occurring Rexinoid, Honokiol, That Activates the Retinoid X Receptor
Kotani, H., Tanabe, H., Mizukami, H., Makishima, M., & Inoue, M. (2010) · Journal of Natural Products · doi:10.1021/np100120c · Cited by 72
Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home
Fitzgerald, M. L., Moore, K. J., & Freeman, M. W. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0318-y · Cited by 72
PPARγ, a Lipid‐Activated Transcription Factor as a Regulator of Dendritic Cell Function
Szatmári, I., Rajnavölgyi, É., & Nagy, L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1366.013 · Cited by 71
Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ
Zhang, H., Xu, X. Y., Chen, L., Chen, J., Hu, L., Jiang, H., & Shen, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028253 · Cited by 71
Yang, M. H., Vásquez, Y., Ali, Z., Khan, I. A., & Khan, S. I. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.07.003 · Cited by 69
Curcumin promotes cholesterol efflux from adipocytes related to PPARgamma–LXRalpha–ABCA1 passway
Dong, S.-Z., Zhao, S., Wu, Z., Yang, J., Xie, X.-Z., Yu, B., & Nie, S. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0978-z · Cited by 69
Anti-Inflammatory Effects of Isoflavones are Dependent on Flow and Human Endothelial Cell PPARγ1
Chacko, B. K., Chandler, R. T., D'Alessandro, T. L., Mundhekar, A. N., Khoo, N. K. H., Botting, N. P., Barnes, S., & Patel, R. P. (2007) · Journal of Nutrition · doi:10.1093/jn/137.2.351 · Cited by 68
Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003640169 · Cited by 65
Dussault, I., & FORMAN, B. M. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00071-x · Cited by 63
Licochalcone E has an antidiabetic effect
Park, H. G., Bak, E., Woo, G., Kim, J. M., Quan, Z., Kim, J. M., Yoon, H., Cheon, S. H., Yoon, G., Yoo, Y., et al. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.03.021 · Cited by 62
Berenson, D. F., Weiss, A. R., Wan, Z., & Weiss, M. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06468.x · Cited by 60
Pferschy‐Wenzig, E., Atanasov, A. G., Malainer, C., Noha, S. M., Kunert, O., Schuster, D., Heiß, E. H., Oberlies, N. H., Wagner, H., Bauer, R., et al. (2014) · Journal of Natural Products · doi:10.1021/np400943b · Cited by 60
Self-citation
Cited by
Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects
Zhang, H., & Tsao, R. (2016) · Current Opinion in Food Science · doi:10.1016/j.cofs.2016.02.002 · Cited by 1,519
An update on PPAR activation by cannabinoids
O'Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 449
Natural Products for the Treatment of Type 2 Diabetes Mellitus
Ríos, J., Francini, F., & Schinella, G. (2015) · Planta Medica · doi:10.1055/s-0035-1546131 · Cited by 446
The Prevalence of Metabolic Syndrome in Children: A Systematic Review of the Literature
Friend, A., Craig, L., & Turner, S. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0122 · Cited by 354
Health benefits of dietary marine DHA/EPA-enriched glycerophospholipids
Zhang, T.-T., Xu, J., Wang, Y.-M., & Xue, C.-H. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.100997 · Cited by 339
Metadata
- Authors
- Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., Schuster, D., Kopp, B., Bauer, R., Stuppner, H., Dirsch, V. M., & Atanasov, A. G.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 92
- Issue
- 1
- Pages
- 73-89
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2067942093
- Cited by
- 594
- References
- 236
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.